Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer
The investigators hypotheses that paclitaxel combined with cisplatin in a weekly-based regimen as neoadjuvant chemotherapy is effective and tolerable for locally advanced breast cancer.
Tubular Breast Cancer|Mucinous Breast Cancer|Invasive Ductal Breast Cancer|Inflammatory Breast Cancer
DRUG: Paclitaxel|DRUG: Cisplatin
Pathological complete response of breast and lymph nodes, after 4 months preoperative treatment
Tolerability and Safety, Descriptive statistics for the treatment will be given on the number of patients whose treatment had to be reduced, delayed or permanently stopped, 4 months during neoadjuvant therapy|Clinical and imaging response, To determine the response rates of the breast tumor and axillary nodes based on physical examination and imaging tests. (sonography, mammography, or MRI) after treatment, 4 months during treatment|regional recurrence free survival (RRFS), RRFS is defined as the time period between registration and first event, 5 years|local recurrence free survival (LRFS), LRFS is defined as the time period between registration and first event, 5 years|distant-disease- free survival (DDFS), DFS is defined as the time period between registration and first event, 5 years|overall survival (OS), OS is defined as the time period between registration and first event, 5 years
In this trial, all the patients will have weekly paclitaxel and cisplatin as neoadjuvant chemotherapy for 4 cycles. Patients with Her2 positive tumor will also receive the trastuzumab.